Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine DOI Creative Commons
Amanda K. Debes, Shaoming Xiao, Emily Egbert

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Jan. 28, 2022

Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose SARS-CoV-2 mRNA series, FDA approved a booster dose for people greater than 12 years old. Limited data exist on whether of vaccine results in protection primary series. We examined total and neutralizing antibodies to spike protein SARS-CoV-2, against Washington-1 (WA-1) variants concern (VOC) including Beta, Delta Omicron longitudinal cohort. Healthcare workers (HWs) were included analysis if serum was collected 1) within 14-44 days post-dose2 an (Timepoint 1, TP1), or 2) at least 8 months 2, TP2), 3) 3, TP3). HWs with prior covid-positive PCR excluded. found there is little no capability series omicron variant, capacity any variant strain tested has been lost by 8-months post two-dose vaccination However, eliminates immune escape observed Neutralizing titers significantly higher all post-boost compared The nature our cohort facilitated paired samples pre boost, showing 15-fold increase neutralization these samples. An provides quantity quality regimen critical provide variant.

Language: Английский

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines DOI Creative Commons
Jia Wei, Koen B. Pouwels, Nicole Stoesser

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(5), P. 1072 - 1082

Published: Feb. 14, 2022

Antibody responses are an important part of immunity after Coronavirus Disease 2019 (COVID-19) vaccination. However, antibody trajectories and the associated duration protection a second vaccine dose remain unclear. In this study, we investigated anti-spike IgG correlates doses ChAdOx1 or BNT162b2 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in United Kingdom general population. 222,493 individuals, found significant boosting by both all ages using different dosing intervals, including 3-week interval BNT162b2. After vaccination, generated higher peak levels than ChAdOX1. Older individuals males had lower with but not ChAdOx1, whereas declines were similar across sexes ChAdOX1 Prior infection significantly increased level half-life vaccines. Anti-spike from vaccination and, to even greater degree, prior infection. At least 67% against was estimated last 2-3 months two doses, 5-8 those without 1-2 years unvaccinated natural A third booster might be needed, prioritized recipients more clinically vulnerable.

Language: Английский

Citations

221
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients DOI Creative Commons
Michel Obéid,

Madeleine Suffiotti,

Céline Pellaton

et al.

JAMA Oncology, Journal Year: 2022, Volume and Issue: 8(5), P. e220446 - e220446

Published: March 10, 2022

There are limited comparative data on the durability of neutralizing antibody (nAb) responses elicited by messenger RNA (mRNA) vaccines against SARS-CoV-2 variants concern (VOCs) in immunocompromised patients and healthy controls.

Language: Английский

Citations

63
Severity of COVID-19 after Vaccination among Hemodialysis Patients DOI Open Access

Damien Ashby,

Ben Caplin, Richard Corbett

et al.

Clinical Journal of the American Society of Nephrology, Journal Year: 2022, Volume and Issue: 17(6), P. 843 - 850

Published: June 1, 2022

Patients receiving hemodialysis are at high risk from coronavirus disease 2019 (COVID-19) and demonstrate impaired immune responses to vaccines. There have been several descriptions of their immunologic severe acute respiratory syndrome 2 (SARS-CoV-2) vaccination, but few studies described the clinical efficacy vaccination in patients on hemodialysis.In a multicenter observational study London population undergoing surveillance PCR testing during period vaccine rollout with BNT162b2 AZD1222, all those positive for SARS-CoV-2 were identified. Clinical outcomes analyzed according predictor variables, including status, using mixed effects logistic regression model. Risk infection was subgroup base Cox proportional hazards model status as time-varying covariate.SARS-CoV-2 identified 1323 different ethnicities (Asian/other, 30%; Black, 38%; White, 32%), 1047 (79%) unvaccinated, 86 (7%) after first-dose 190 (14%) second-dose vaccination. The majority had mild course; however, 515 (39%) hospitalized, 172 (13%) died. Older age, diabetes, suppression associated greater illness severity. In models adjusted comorbidity, time period, prior two-dose 75% (95% confidence interval, 56 86) lower admission 88% 70 95) fewer deaths compared unvaccinated patients. No loss protection seen over 65 years or increasing since no difference between types.These data substantially COVID-19 dialysis who become infected SARS-CoV-2.

Language: Английский

Citations

48
Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults DOI
Janna R. Shapiro, Ioannis Sitaras,

Han Sol Park

et al.

Clinical Infectious Diseases, Journal Year: 2022, Volume and Issue: 75(Supplement_1), P. S61 - S71

Published: May 24, 2022

Male sex and old age are risk factors for severe coronavirus disease 2019, but the intersection of aging on antibody responses to acute respiratory syndrome 2 (SARS-CoV-2) vaccines has not been characterized.

Language: Английский

Citations

44
Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis DOI Creative Commons
Joseph E. Ebinger, Sandy Joung, Yunxian Liu

et al.

BMJ Open, Journal Year: 2022, Volume and Issue: 12(5), P. e059994 - e059994

Published: May 1, 2022

Objectives We sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment BNT162b2 vaccination. Design This study is a 10-month cohort healthcare workers serially measured anti-spike protein IgG (IgG-S) levels using mixed linear models examine their associations participant characteristics. Setting A large, multisite academic medical centre Southern California, USA. Participants total 843 met inclusion criteria including an initial course vaccination, complete history at least two blood samples for analysis. Patients had average age 45±13 years, were 70% female 7% prior SARS-CoV-2 infection. Results Vaccine-induced IgG-S remained positive range 99.6% individuals up 10 months after Prior infection was primary correlate sustained higher postvaccination (partial R 2 =0.133), 1.74±0.11 SD (p<0.001). Female sex (beta 0.27±0.06, p<0.001), younger (0.01±0.00, p<0.001) absence hypertension (0.17±0.08, p=0.003) also persistently responses. Notably, augmented (−0.42 male sex, p=0.08) modified (1.17, p=0.001), such that infection-naïve lower whereas infected exhibited over time. Conclusions While remains mRNA vaccination most adults, determinants include infection, hypertension. Certain appear significantly by status. These findings offer insights regarding may influence ‘hybrid’ immunity conferred natural combined

Language: Английский

Citations

30
Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine DOI Creative Commons
Shohei Yamamoto,

Yusuke Oshiro,

Natsumi Inamura

et al.

Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 29(9), P. 1201.e1 - 1201.e5

Published: May 24, 2023

To examine the differences in durability and its determinants of humoral immunity following 2- 3-dose COVID-19 vaccination.Throughout pandemic, we evaluated anti-spike IgG antibody titers mRNA vaccine recipients over time among staff a medical research center Tokyo. Linear mixed models were used to estimate trajectories from 14 180 days after last immune-conferred event (vaccination or infection) compare waning rates across prior infection vaccination status, background factors infection-naïve participants.A total 6901 measurements 2964 participants (median age, 35 years; 30% male) analyzed. Antibody rate (percentage per 30 [95% CI]) was slower 3 doses (25% [23-26]) than 2 (36% [35-37]). Participants with hybrid had further rates: 2-dose plus (16% [9-22]); (21% [17-25]). Older male sex, obesity, coexisting diseases, immunosuppressant use, smoking, alcohol drinking associated lower titers, whereas these associations disappeared doses, except for sex (lower female participants) use. waned slightly faster older participants, females, drinkers it did not differ sex.The conferred higher durable previous modestly enhanced durability. The levels at given point speed differed factors; however, mostly diminished doses.

Language: Английский

Citations

21
Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID‐19 Vaccination Antibody Response DOI Creative Commons
Michelle Petri, Daniel Joyce,

Kristin Haag

et al.

Arthritis Care & Research, Journal Year: 2023, Volume and Issue: 75(9), P. 1878 - 1885

Published: Jan. 30, 2023

The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE) versus those without SLE. Some immunosuppressive medications increase and decrease the efficacy vaccination. Consensus documents have suggested management strategies for handling to vaccine efficacy, but benefit such has not been proven. current study was undertaken determine effect drugs on response

Language: Английский

Citations

19
COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response DOI
Ethan G. Dutcher, Elissa Epel, Ashley E. Mason

et al.

Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: 177(7), P. 892 - 900

Published: June 10, 2024

Concern about side effects is a common reason for SARS-CoV-2 vaccine hesitancy.

Language: Английский

Citations

7
Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers – ORCHESTRA project DOI Creative Commons
Giulia Collatuzzo, Giovanni Visci, Francesco Saverio Violante

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 29, 2022

Background The duration of immune response to COVID-19 vaccination is major interest. Our aim was analyze the determinants anti-SARS-CoV-2 IgG titer at 6 months after 2-dose in an international cohort vaccinated healthcare workers (HCWs). Methods We analyzed data on levels Spike antibodies and sociodemographic clinical characteristics 6,327 HCWs from 8 centers Germany, Italy, Romania Slovakia. Time between 1 st dose serology ranged 150-210 days. Serological were log-transformed account for skewness distribution normalized by dividing them center-specific standard errors, obtaining standardized values. fitted multivariate regression models estimate cohort-specific relative risks (RR) increase deviation log antibody level corresponding 95% confidence interval (CI), finally combined random-effects meta-analyses. Results A 6-month serological detected 99.6% HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection 2.26, 1.73-2.95) two vaccine doses 1.50, 1.22-1.84) predicted higher titer, contrary since last 10-day 0.94, 0.91-0.97) age 10-year 0.87, 0.83-0.92). M-RNA-based vaccines (p&lt;0.001) heterologous 2.46, 1.87-3.24, one cohort) associated with increased levels. Conclusions gender, young age, infection, doses, m-RNA months. These results corroborate previous findings offer valuable comparison trends observed longer follow-ups.

Language: Английский

Citations

28
Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals DOI Creative Commons

Eustache Paramithiotis,

Scott Sugden,

Eszter Papp

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: May 26, 2022

COVID-19 vaccine clinical development was conducted with unprecedented speed. Immunity measurements were concentrated on the antibody response which left significant gaps in our understanding how robust and long-lasting immune protection develops. Better cellular will fill those gaps, especially elderly immunocompromised populations not only have highest risk for severe infection, but also frequently inadequate responses. Although immunity are more logistically complex to conduct trials compared measurements, feasibility benefit of doing them has been demonstrated so should be widely adopted. Adding metrics provide a deeper overall vaccination, significantly inform vaccination strategies most vulnerable populations. monitoring substantially other efforts, indeed any therapies that involve system as part therapeutic strategy.

Language: Английский

Citations

25